LEADER 03989nam 2200817z- 450 001 9910557287803321 005 20210501 035 $a(CKB)5400000000041162 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68938 035 $a(oapen)doab68938 035 $a(EXLCZ)995400000000041162 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAntimicrobial Resistance in Horses 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (124 p.) 311 08$a3-03936-712-9 311 08$a3-03936-713-7 330 $aAntimicrobial resistance (AMR) is a global problem with extremely complex epidemiology involving the direct and indirect transmission of antibiotic resistant pathogens and mobile genetic elements between humans, animals, and the environment. AMR is, therefore, recognized as a 'One Health' issue. Data that describe AMR prevalence and trends are required to enable the judicious and prudent use of antimicrobials in animals, which has implications both from veterinary and animal welfare aspects as well as from a zoonotic and public health perspective. Horses are a potential reservoir of AMR for humans due to close human-animal contact, as was demonstrated with shared human and horse methicillin-resistant Staphylococcus aureus (MRSA) strains causing outbreaks in equine hospitals. Extended-spectrum beta-lactamase-producing Enterobacteriaceae, considered as clinically and economically important to the AMR burden in human and veterinary medicine, has been reported in both community and clinic equine populations. Strains of Enterobacteriaceae pose a major worldwide threat due to the geographical expansion of ESBL-producing clones as well as the horizontal interspecies dissemination of ESBL-encoding plasmids and genes. In human medicine, ESBL-E infection is associated with increased morbidity, mortality, length of hospital stay, delay of targeted appropriate treatment, and higher costs. These issues also need to be addressed in horses. This Special Issue on AMR in horses encompasses several papers that describe the prevalence, risk factors, and molecular data on MDR bacteria in healthy horses in Canada, Japan, Spain, and Israel, in addition to papers that describe the clinical impact of MDR bacteria in diseased horses in Austria, USA, France and Israel. 606 $aHumanities$2bicssc 606 $aSocial interaction$2bicssc 610 $aAmpC 610 $aAmpC ?-lactamase 610 $aantibiotic resistance 610 $aantibiotic-resistance 610 $aantimicrobial resistance 610 $abeta-lactamase 610 $acephalosporinase 610 $aCTX-M-1 610 $aEnterobacteriaceae 610 $aepidemiology 610 $aequine 610 $aESBL 610 $aESBL-E 610 $aESBL-E acquisition 610 $aEscherichia coli 610 $aextended-spectrum ?-lactamase 610 $afarm 610 $afoal 610 $ahealthy horses 610 $ahorse 610 $ahorse pathogens 610 $ahorses 610 $aKlebsiella pneumoniae 610 $alukPQ 610 $amicrobiota 610 $aMSSA 610 $amultidrug resistance 610 $an/a 610 $aNorth America 610 $arisk factors 610 $ashedding 610 $aSHV 610 $aST1640 610 $astaphylococci 610 $aumbilical infection 610 $a?-lactamases 615 7$aHumanities 615 7$aSocial interaction 700 $aSteinman$b Amir$4edt$01293810 702 $aNavon-Venezia$b Shiri$4edt 702 $aSteinman$b Amir$4oth 702 $aNavon-Venezia$b Shiri$4oth 906 $aBOOK 912 $a9910557287803321 996 $aAntimicrobial Resistance in Horses$93022735 997 $aUNINA